Chile Cardiovascular Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The chile cardiovascular devices market size was valued at USD 272.98 million in 2025 and estimated to grow from USD 293.94 million in 2026 to reach USD 425.55 million by 2031, at a CAGR of 7.68% during the forecast period (2026-2031). This report is Segmented by Device Type (Diagnostic and Monitoring Devices [ECG Systems, Remote Cardiac Monitor, and More], and Therapeutic and Surgical Devices [Coronary Stents, and More]), Application (Coronary Artery Disease, Arrhythmia & Conduction Disorders, and More), End User (Hospitals & Clinics, and More). The Market Forecasts are Provided in Terms of Value (USD).

Chile Cardiovascular Devices Market Trends and Insights

Rising Prevalence of Ischemic Heart Disease Linked to Dietary Transitions in Urban Chile

Food-environment studies in Santiago show that low-income boroughs with limited access to fresh produce register higher ischemic heart-disease rates than wealthier districts, a disparity persisting despite the front-of-pack labelling law. Consequently, coronary interventions remain the largest application within the Chile cardiovascular devices market, pushing hospitals to increase inventories of drug-eluting stents and balloon catheters. Wearable blood-pressure cuffs and portable ECG recorders are also proliferating as community clinics deploy them for primary-prevention campaigns. Device makers leverage these urban programmes to pilot AI-powered analytics that flag arrhythmogenic patterns before symptom onset, broadening preventive care.

Mandatory Private Health Insurance (ISAPRE) Coverage Expansion for Cardiac Implants Effective 2023

ISAPRE beneficiaries now receive reimbursement for pacemakers, CRT devices and implantable defibrillators, lifting procedure volumes in private hospitals by double-digit percentages during 2024. Suppliers initially recorded stronger sales but must navigate a Supreme Court ruling that caps premium adjustments using risk-factor tables, a shift that could compress margins on high-end implants. Nevertheless, the policy continues to draw patients from public waitlists into private suites, underpinning forecast growth in the Chile cardiovascular devices market during the next two years.

Limited Reimbursement for Next-Generation Bioabsorbable Stents by FONASA

While GES guarantees cover acute myocardial-infarction treatment, hospital budgets rarely stretch to the price premium on absorbable scaffolds, constraining penetration to private payers. The resulting supply imbalance limits scale efficiencies, keeping per-unit costs high and delaying broader uptake across the Chile cardiovascular devices market. Clinicians advocate for cost-effectiveness reviews, yet funding cycles suggest only gradual policy relaxation over the next four years.

Other drivers and restraints analyzed in the detailed report include:

• Growth of Local Interventional Cardiology Centers Accredited for TAVI Procedures
• Government’s National Cardiovascular Health Program Expanding Device Procurement in Public Hospitals
• Peso Volatility Driving Up Import Costs for High-End Implantables

Segment Analysis

Chile cardiovascular devices market leadership by therapeutic and surgical equipment remains intact, yet diagnostics are closing the gap as tele-cardiology matures. In value terms, diagnostic and monitoring devices will outpace the broader market at an 8.63% CAGR through 2031, leveraging the national network that analyses more than 50,000 ECGs monthly. Portable recorders and AI-enabled wearables feed real-time data to cardiology hubs, reducing STEMI mortality from 12% to 8.6% since 2024.

Therapeutic and surgical systems accounted for 68.73% of the Chile cardiovascular devices market size in 2025, underscoring enduring demand for drug-eluting stents and rhythm-management implants. Uptake is amplified by ISAPRE reimbursement, especially for CRT-P devices that restore ventricular synchrony in heart-failure cohorts. Robotic TMVR cases in Santiago now demonstrate feasibility for fully percutaneous mitral repair, widening indications and seeding demand for advanced valve prostheses. Nevertheless, currency swings elevate import costs, prompting hospitals to consolidate purchases under multi-year tenders tied to peso hedges.

Complete Report Scope:

• By Device Type
  • Diagnostic & Monitoring Devices
    • ECG Systems
    • Remote Cardiac Monitor
    • Cardiac MRI
    • Cardiac CT
    • Echocardiography / Ultrasound
    • Fractional Flow Reserve (FFR) Systems
  • Therapeutic & Surgical Devices
    • Coronary Stents
      • Drug-Eluting Stents
      • Bare-Metal Stents
      • Bioresorbable Stents
    • Catheters
      • PTCA Balloon Catheters
      • IVUS/OCT Catheters
    • Cardiac Rhythm Management
      • Pacemakers
      • Implantable Cardioverter Defibrillators
      • Cardiac Resynchronization Therapy Devices
    • Heart Valves
      • TAVR/TAVI
      • Mechanical Valves
      • Tissue/Bioprosthetic Valves
    • Ventricular Assist Devices
    • Artificial Hearts
    • Grafts & Patches
    • Other Cardiovascular Surgical Devices
• By Application
  • Coronary Artery Disease
  • Arrhythmia & Conduction Disorders
  • Heart Failure & Cardiomyopathy
  • Structural & Congenital Heart Defects
  • Peripheral Vascular Disease
• By End User
  • Hospitals & Clinics
  • Home Care Settings
  • Others

List of Companies Covered in this Report:

• Abbott Laboratories
• Boston Scientific
• Terumo
• BIOTRONIK
• Koninklijke Philips
• GE HealthCare Technologies
• Siemens Healthineers
• Mindray Bio-Medical Electronics Co., Ltd.
• Nipro
• Stryker

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support